Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission

Radiology

Volumn 258, Issue 3, 2011, Pages 821-831

  Chen, Bang Bin ^a   Hsu, Chao Yu ^a   Yu, Chih Wei ^a   Hou, Hsin An ^a   Liu, Chieh Yu ^b   Wei, Shwu Yuan ^a   Chou, Wen Chien ^a   Tien, Hwei Fang ^a   Shih, Tiffany Ting Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GADODIAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952293432     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10100995     Document Type: Article

References (49)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-1907. (Pubitemid 44794525)
2. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66(3):181-193. (Pubitemid 351608299)
3. Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010;116(21):5012-5021.
4. de Lima M, Strom SS, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 1997;90(12):4719-4724. (Pubitemid 28007184)
5. Yanada M, Borthakur G, Garcia-Manero G, et al. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 2008;32(10):1505-1509.
6. Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol 2004;22(12):2410-2418. (Pubitemid 41115398)
7. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104(10):3078-3085. (Pubitemid 39517010)
8. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 2000;95(1):72-77. (Pubitemid 30017227)
9. Hou HA, Shih TT, Liu CY, et al. Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica 2010;95(8):1420-1424.
10. Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology 2009;251(2):317-335.
11. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17(5):509-520. (Pubitemid 36528666)
12. Shih TT, Hou HA, Liu CY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009;113(14):3161-3167.
13. Matuszewski L, Persigehl T, Wall A, et al. Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience. Radiology 2007;242(1):217-224. (Pubitemid 44956027)
14. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007;13(2 pt 1):475-481. (Pubitemid 46225352)
15. Rahmouni A, Montazel JL, Divine M, et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003;229(3):710-717. (Pubitemid 37467573)
16. Hawighorst H, Libicher M, Knopp MV, Moehler T, Kauffmann GW, Kaick G. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 1999;10(3):286-294. (Pubitemid 29463111)
17. Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, Newstead GM. Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers. Radiology 2010;254(3):680-690.
18. Koh TS, Thng CH, Lee PS, et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008;249(1):307-320.
19. Nosàs-Garcia S, Moehler T, Wasser K, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 2005;22(1):154-162. (Pubitemid 40885141)
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103(4):620-625.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21(24):4642-4649. [Published correction appears in J Clin Oncol 2004;22(3):576.]
22. Shih TT, Tien HF, Liu CY, Su WP, Chan WK, Yang PC. Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia. Leukemia 2006;20(2):357-362. (Pubitemid 43148680)
23. Shih TT, Chang CJ, Tseng WY, et al. Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology 2004;231(1):24-30. (Pubitemid 38375404)
24. Chen WT, Shih TT, Chen RC, et al. Vertebral bone marrow perfusion evaluated with dynamic contrast-enhanced MR imaging: significance of aging and sex. Radiology 2001;220(1):213-218.
25. Montazel JL, Divine M, Lepage E, Kobeiter H, Breil S, Rahmouni A. Normal spinal bone marrow in adults: dynamic gadolinium-enhanced MR imaging. Radiology 2003;229(3):703-709. (Pubitemid 37467572)
26. Shih TT, Liu HC, Chang CJ, Wei SY, Shen LC, Yang PC. Correlation of MR lumbar spine bone marrow perfusion with bone mineral density in female subjects. Radiology 2004;233(1):121-128. (Pubitemid 39280966)
27. Griffith JF, Yeung DK, Antonio GE, et al. Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology 2005;236(3):945-951. (Pubitemid 41170858)
28. Griffith JF, Wang YX, Zhou H, et al. Reduced bone perfusion in osteoporosis: likely causes in an ovariectomy rat model. Radiology 2010;254(3):739-746.
29. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15(4):621-628.
30. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7(1):91-101. (Pubitemid 28365643)
31. Zwick S, Brix G, Tofts PS, et al. Simulation-based comparison of two approaches frequently used for dynamic contrast-enhanced MRI. Eur Radiol 2010;20(2):432-442.
32. Yang X, Liang J, Heverhagen JT, et al. Improving the pharmacokinetic parameter measurement in dynamic contrast-enhanced MRI by use of the arterial input function: theory and clinical application. Magn Reson Med 2008;59(6):1448-1456. (Pubitemid 351813276)
33. Hillengass J, Zechmann C, Bäuerle T, et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 2009;15(9):3118-3125.
34. Moehler TM, Hawighorst H, Neben K, et al. Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 2001;93(6):862-868. (Pubitemid 32756756)
35. Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20(1):29-34.
36. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30(3):253-270.
37. Williams B, Mandrekar JN, Mandrekar SJ, Cha SS, Furth AF. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Technical Reports series no. 79. Rochester, Minn: Department of Health Science Research, Mayo Clinic, 2006;1-26.
38. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43(2):121-137. (Pubitemid 36715216)
39. Padró T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95(8):2637-2644. (Pubitemid 30210544)
40. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96(2):189-195. (Pubitemid 46160619)
41. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16(4):407-422. (Pubitemid 35167876)
42. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3):223-232.
43. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76(Spec Issue):S60-S80. (Pubitemid 39530317)
44. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56(8):607-620. (Pubitemid 35023779)
45. Verstraete KL, Van der Woude HJ, Hogendoorn PC, De-Deene Y, Kunnen M, Bloem JL. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J Magn Reson Imaging 1996;6(2):311-321. (Pubitemid 126701461)
46. Kiessling F, Krix M, Heilmann M, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol 2003;38(8):516-524. (Pubitemid 36875548)
47. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62. (Pubitemid 40093472)
48. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-1027. (Pubitemid 46202320)
49. Ma HT, Griffith JF, Yeung DK, Leung PC. Modified brix model analysis of bone perfusion in subjects of varying bone mineral density. J Magn Reson Imaging 2010;31(5):1169-1175.